ArticleBioinformatics (Oxford, England)2019
A Drug-Side Effect Context-Sensitive Network approach for drug target prediction.
Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Targeting protein protein interactions and their modulators to enable new therapeutic strategies for human diseases.NPJ systems biology and applications · 2026Review
- Curated and Structure-Based Drug-Target Interactions Improve Underprediction of Drug Side Effects in Network Models.Journal of chemical information and modeling · 2026Article
- Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework.Communications biology · 2023Article
- KG-Predict: A knowledge graph computational framework for drug repurposing.Journal of biomedical informatics · 2022Article
- Exploring complex and heterogeneous correlations on hypergraph for the prediction of drug-target interactions.Patterns (New York, N.Y.) · 2021Article
- NeuRank: learning to rank with neural networks for drug-target interaction prediction.BMC bioinformatics · 2021Article
- Gut-microbiota-microglia-brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization.Alzheimer's research & therapy · 2021Article
- Quantitative prediction model for affinity of drug-target interactions based on molecular vibrations and overall system of ligand-receptor.BMC bioinformatics · 2021Article
- Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses.Molecular psychiatry · 2021Article
- Supervised Analysis for Phenotype Identification: The Case of Heart Failure Ejection Fraction Class.Bioengineering (Basel, Switzerland) · 2021Article
- CoMNRank: An integrated approach to extract and prioritize human microbial metabolites from MEDLINE records.Journal of biomedical informatics · 2020Article
- Combining phenome-driven drug-target interaction prediction with patients' electronic health records-based clinical corroboration toward drug discovery.Bioinformatics (Oxford, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
summaryComputational drug target prediction has become an important process in drug discovery. Network-based approaches are commonly used in computational drug-target interaction (DTI) prediction. Existing network-based approaches are limited in capturing the contextual information on how diseases, drugs and genes are connected. Here, we proposed a context-sensitive network (CSN) model for DTI prediction by modeling contextual drug phenotypic relationships. We constructed a Drug-Side Effect Context-Sensitive Network (DSE-CSN) of 139 760 drug-side effect pairs, representing 1480 drugs and 5868 side effects. We also built a protein-protein interaction network (PPIN) of 15 267 gene nodes and 178 972 weighted edges. A heterogeneous network was built by connecting the DSE-CSN and the PPIN through 3684 known DTIs. For each drug on the DSE-CSN, its genetic targets were predicted and prioritized using a network-based ranking algorithm. Our approach was evaluated in both de novo and leave-one-out cross-validation analysis using known DTIs as the gold standard. We compared our DSE-CSN-based model to the traditional similarity-based network (SBN)-based prediction model. The results suggested that the DSE-CSN-based model was able to rank known DTIs highly. In a de novo cross-validation, the area under the receiver operating characteristic (ROC) curve was 0.95. In a leave-one-out cross-validation, the average rank was top 3.2% for known DTIs. When it was compared to the SBN-based model using the Precision-Recall curve, our CSN-based model achieved a higher mean average precision (MAP) (0.23 versus 0.19, P-value<1e-4) in a de novo cross-validation analysis. We further improved the CSN-based DTI prediction by differentially weighting the drug-side effect pairs on the network and showed a significant improvement of the MAP (0.29 versus 0.23, P-value<1e-4). We also showed that the CSN-based model consistently achieved better performances than the traditional SBN-based model across different drug classes. Moreover, we demonstrated that our novel DTI predictions can be supported by published literature. In summary, the CSN-based model, by modeling the context-specific inter-relationships among drugs and side effects, has a high potential in drug target prediction. AVAILABILITY AND IMPLEMENTATION: nlp/case/edu/public/data/DSE/CSN_DTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.